Periodic Reporting for period 2 - Soraprazan (Soraprazan - a new regenerative therapy for Stargardt's disease)

A consortium of eight partners prepared and started a phase 2, proof of concept, clinical study with Remofuscin in adult patients with Stargardt’s disease. Active ingredient of the drug is Soraprazan, which gave the name to this EU financed project. For the clinical study...